Study: Pfizer COVID Treatment Pill Showed No Benefit To Younger Adults
Newsy
Results from a 109,000-patient study show that Paxlovid had no measurable benefit in patients between the ages of 40 and 65.
Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
The results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government's use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative.
The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That's consistent with earlier results used to authorize the drug in the U.S. and other nations.
